biostudies-literatureUnknown54(5)Nagahara AAstellas Pharma Inc.<h4>Background</h4>Alternative anti-androgen therapy has been widely used as a first-line treatment for castration-resistant prostate cancer, and it may affect treatment outcome of subsequent agents targeting the androgen receptor axis. We conducted the prospective observational DELC (Determination of Enzalutamide Long-term safety and efficacy for Castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy) study to evaluate the efficacy of enzalutamide in patients with castration-resistant prostate cancer who underwent prior combined androgen blockade with bicalutamide and then alternative anti-androgen therapy with flutamide.<h4>Methods</h4>The DELC study enrolled 163 Japanese patients with castration-resistant prostatJapanese journal of clinical oncology584-591https://www.ebi.ac.uk/biostudies/studies/S-EPMC11075733biostudies-literatureDetermination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.PMC11075733Nonomura NNishimura KTakao TOkada KTakada SIwanishi TMatsumura SUemura MInoue HFujita KKato TTakada TUjike TNakata WTsujihata MIshizuya YKobayashi YSato MKawashima ANagahara AHatano KfalseDetermination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.<h4>Background</h4>Alternative anti-androgen therapy has been widely used as a first-line treatment for castration-resistant prostate cancer, and it may affect treatment outcome of subsequent agents targeting the androgen receptor axis. We conducted the prospective observational DELC (Determination of Enzalutamide Long-term safety and efficacy for Castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy) study to evaluate the efficacy of enzalutamide in patients with castration-resistant prostate cancer who underwent prior combined androgen blockade with bicalutamide and then alternative anti-androgen therapy with flutamide.<h4>Methods</h4>The DELC study enrolled 163 Japanese patients with castration-resistant prostat2024-01-01T00:00:00Z2024 May2026-04-08T19:39:41.697Z2026-04-08T14:12:14.84ZS-EPMC110757333830545110.1093/jjco/hyae004